Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) is a specialty pharmaceutical company headquartered in Lake Forest, Illinois. The company is dedicated to advancing patient care through the commercialization of differentiated products in the areas of neurology, orphan, and specialty medicines. Assertio's portfolio includes three FDA-approved products:
- Gralise: Extended-release tablets for the management of postherpetic neuralgia.
- CAMBIA: A solution for the acute treatment of migraine attacks with or without aura in adults.
- Zipsor: Liquid-filled capsules for the relief of mild to moderate pain.
In August 2023, Assertio completed the acquisition of Spectrum Pharmaceuticals, Inc., bringing the innovative ROLVEDON™ to its portfolio. This addition is poised to diversify Assertio’s revenue base and enhance its commercial capabilities. Despite some challenges, including competition from generic drugs, Assertio remains committed to leveraging its digital non-personal sales model to drive growth and efficiency.
Financially, Assertio reported substantial cash flow from operations and maintained a robust cash position. The company continues to explore strategic acquisitions and licensing opportunities to expand its portfolio and drive long-term growth. Recent leadership changes and the appointment of experienced executives underscore Assertio’s commitment to optimizing its commercial strategies and maintaining financial stability.
Assertio’s forward-looking strategy involves not only enhancing its current product offerings but also advocating for patient access to medications through legislative efforts. The company’s non-personal promotional model and strategic acquisitions ensure its adaptability in a competitive market. For more detailed financial data and corporate updates, visit Assertio's investor relations website.
Assertio Holdings (ASRT) plans to disclose its second quarter 2022 financial results on August 8, 2022, prior to market opening. The management will host a live conference call at 11:30 a.m. ET to discuss the results. Interested parties can access the webcast via the company's investor relations website and should connect 10 minutes early to allow time for any necessary software downloads. A replay of the call will be available shortly after its conclusion.
Assertio specializes in differentiated pharmaceutical products, aiming to enhance its commercial portfolio through strategic opportunities.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced on July 12, 2022, that it granted new employees a total of 17,772 restricted stock units (RSUs) and 18,553 stock options effective July 1, 2022. This incentive aligns with NASDAQ Listing Rule 5635(c)(4) and is contingent on the employees' continued service. The options have an exercise price of $3.15 per share, matching the company's stock closing price on the grant date, with vesting scheduled over three years.
Assertio Holdings (NASDAQ: ASRT) announced its participation in the LD Micro Invitational XII Conference from June 7-9, 2022 at the Four Seasons Hotel in Westlake Village, CA. The Company will present on June 8, 2022, at 3:00 PM PT in Track 1, with opportunities for 1:1 meetings with investors throughout the day. Presentation information will be available on the event day at assertiotx.com. Investors can contact LD Micro or Matt Kreps from Darrow Associates for meeting inquiries.
Assertio Holdings, Inc. (ASRT) reported strong financial results for Q1 2022, with net product sales rising 37% year-over-year to $35.5 million. Net income reached $9.1 million, up 99% from the previous year, driven by higher sales and improved gross profit margin of 88%. The company also raised its full-year non-GAAP adjusted EBITDA guidance to $66-$74 million, reinforcing its commitment to growth and a goal of adding $40 million in gross profit by 2024.
Assertio Holdings, Inc. (NASDAQ: ASRT) is set to release its first quarter 2022 financial results on May 9, 2022, after market close. A live webcast of the earnings conference call will follow at 4:30 p.m. ET. Investors can access the webcast and related materials through the company's investor relations website. Assertio focuses on specialty pharmaceuticals, leveraging a non-personal promotional model while expanding its product portfolio through both existing and new opportunities.
Assertio Holdings, Inc. (NASDAQ: ASRT) and BlinkRx have announced a collaboration aimed at facilitating patient access to Otrexup, a once-weekly auto-injector that delivers methotrexate. This partnership seeks to eliminate barriers to medication access for patients and healthcare professionals. The BlinkRx program provides patients with transparent pricing, free home delivery, and personalized support. Assertio's CEO, Dan Peisert, expressed enthusiasm for this digital solution, aligning with the company's strategy for enhanced patient engagement.
Assertio Holdings, Inc. (ASRT) reported a 7% increase in fourth quarter net product sales to $32.2 million and $109.4 million for the full year 2021, driven by price favorability for Cambia and Indocin. The non-GAAP adjusted EBITDA surged 118% year-over-year to $17.8 million in Q4. The company provided 2022 guidance for net product sales between $126 million and $136 million and adjusted EBITDA from $64 million to $72 million. Assertio completed the acquisition of Otrexup, contributing to its growth strategy.
Assertio Holdings (NASDAQ: ASRT) will release its fourth quarter and full year 2021 financial results on March 9, 2022, before markets open. A live webcast of the earnings conference call is scheduled for 9:00 AM ET the same day. Investors can access details via the investor relations website. Assertio focuses on creating a differentiated pharmaceutical portfolio through product innovation and acquisitions.
Assertio Holdings (NASDAQ: ASRT) announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Dan Peisert and CFO Paul Schwichtenberg will represent the company. An investor presentation is now available for on-demand viewing on the Assertio Investor Relations website for 30 days. Assertio focuses on commercializing differentiated pharmaceutical products in neurology, hospital care, and pain management. For more details, visit Assertio's website.
Assertio Holdings, Inc. (Nasdaq: ASRT) has announced the acquisition of Otrexup (methotrexate) from Antares Pharma for a total of $44 million, including $18 million paid upfront. This acquisition, the first since 2015, aims to enhance Assertio's growth and leverage its digital platform for commercialization. Assertio raised its full-year net product sales guidance to over $108 million and adjusted EBITDA to over $48 million for 2021, fueled by strong existing product sales and expected contributions from Otrexup.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
What products does Assertio Holdings, Inc. offer?
What is the significance of Assertio’s acquisition of Spectrum Pharmaceuticals?
How does Assertio promote its products?
What are some of Assertio's recent financial highlights?
Who are some of the key leadership figures at Assertio?
What challenges does Assertio face with generic competition?
What is Assertio’s strategy for long-term growth?
How can investors access information about Assertio?
What role does Assertio play in legislative advocacy?
What is Assertio’s approach to sales and marketing?
